A venture capital firm based in Singapore, with an additional office in the US makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia and/or Singapore. The firm is actively seeking new investment opportunities.
In the Life Sciences, the firm is currently seeking medical devices, synthetic biology and digital health. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.
The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm With US & Asia Offices Seeks New Investments in Medical Devices, Synthetic Biology, and Digital Health
11 MayHot Investor Mandate: Investment Arm of Large Corporation Invests in Accountable Care-Centered Solutions, Targeting the USA Market
11 MayWith multiple offices throughout the US, a new business unit within a large corporation is focused on improving the quality, affordability and equity of employer-sponsored health care. This new investment arm is investing from the corporate’s balance sheet in early-stage and advanced health companies that offer accountable care and value-based solutions to employers and employees.
The firm’s “sweet spot” is in Series B and beyond. While the organization primarily deploys growth equity capital, it can consider making investments into earlier stage companies. The firm can invest in, and will consider opportunities outside of the U.S. market, but these opportunities must be focused on the employer-sponsored insurance market in the U.S.
Within healthcare, the firm invests primarily in accountable care-centered solutions and integrated disease management programs. The firm’s core focus areas are care delivery, priority conditions, analytics & enablers of advanced medical care, and pharma services.
The firm is also focused on health solutions that can be implemented in a remote or at-home setting, reducing the burden of patients. In terms of stage of development, the firm expects to see customer traction and revenue generation taking place – companies who are still developing a working product that has yet to be implemented will generally be considered too early for investment.
The firm seeks to invest in companies that have established substantial validation on their product/technology. The firm has board representation with each of the companies it has invested in and has typically served as a syndicate partner to lead investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Women-Led VC Seeks to Invest in Life Science Companies Addressing Women’s Health, Prioritizing Europe-Based Opportunities
11 MayA women-led venture capital is raising a new venture fund and is looking to invest in life science companies that address women’s health between Seed to Series A in Europe, the UK, and Israel, eventually scaling to the U.S as well. Typical check sizes range anywhere between £500k-1M for the first round and will double down up to £2M in Series A. The firm is open to acting as a lead investor for smaller rounds, however they are currently co-investing especially as they start to invest in the U.S.
The firm is open to any life science sector including therapeutics, diagnostics, medical devices, digital health, etc. in the clinical stage as long as the company addresses women’s health. This includes innovations that solely, disproportionately, and/or differently affect women, such as menopause, autoimmune diseases, and heart disease. The firm is open to anywhere from therapeutics and genomics to consumer products. The firm requires to see clinical data and efficacy in the technology. In terms of medical devices, the firm is open to all classes. The only exception that the firm does not invest in is pharmaceuticals.
The firm does not have specific team requirements, however the firm will take a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Introducing the Panelists at RESI Boston June
4 MayBy Momo Yamamoto, Investor Research Analyst, LSN
Time is flying by, and there is only a month left until RESI Boston! As a refresher, RESI Boston will be a 3-day hybrid conference, taking place on June 5th – 7th. June 5th will be in-person at the Westin Copley Place, featuring Innovator’s Pitch Challenge (IPC) sessions, 7 investor panels, and educational workshops followed by all-day virtual partnering on June 6th – 7th.
Life Science Nation is excited to announce the 20+ panelists who have been selected to speak on our investor panels at RESI Boston. Panel topics include: Big Pharma, Women’s Health, Cell & Gene Therapy, Corporate VC, CNS Diseases, Medtech Strategics, and Digital Health. At this RESI, we will be featuring two new panel topics, Women’s Health and CNS Diseases. Join our seasoned panelists from a wide range of sectors to get the latest insight on trends, emerging topics, advice, and more!
Take a look below for our panelists who will be giving you the latest scoop:
 Elizabeth Bailey Managing Director RH Capital |
 Caleb Bell Venture Partner Corundum Systems Biology |
 Nat Brinn Partner VC23 |
 Frederic Cedrone Vice President, Corporate Innovation Catalent Strategic Ventures |
 Geoff Dacosta Director, Business Development and Licensing Philips Healthcare |
 Neel Desai Business Development & Licensing Biogen |
 Marissa Fayer U.S. Partner Goddess Gaia Ventures |
 Tom Gibbs Director Debiopharm Innovation Fund |
 Lucio Iannone VP of Investments Leaps by Bayer |
 Jotthe Kannappan Associate Intuitive Surgical |
 Arianne Kidder Principal Seae Ventures |
 Joan Koerber-Walker Co-Founder and Managing Member AZBio |
 Adam Kundzewicz Executive Director Boehringer Ingelheim Venture Fund |
 Linda Li Venture Partner Cleveland Clinic Ventures |
 Wasim Malik Co-Founder and Managing Partner Iaso Ventures |
 Amanda Mason Director, Global Head of Inflammation Search & Evaluation, Business Development Amgen |
 John Pennett Angel Investor Mid Atlantic Bio Angels |
 Jane Rho Investor, Venture Fund DaVita Venture Group |
 Ronak Savla Director, Strategic Ventures Catalent Strategic Ventures |
 Yaniv Sneor Founding Member Mid Atlantic Bio Angels |
 Ashim Subedee Director, Catalyst Office Division of Research Innovation and Ventures (DRIVe) |
 David Uffer Vice President, MedTech General Inception |
 Matt Weinberg Partner Max Ventures |
 Sonia Weiss Co-Founder & Managing Partner WPSS.bio |
 Andrew Wong Global Head of Bayer CoLabs Bayer |
 Lu Zhang Managing Partner Fusion Fund |
Have you heard about the Audience Access Pass (AAP) at RESI Boston June?
4 MayBy Antoinette Lowre, Manager of Business Development, LSN
The AAP is a cost-effective way to attend RESI Boston on Monday, June 5th, and network with over 600 early-stage life science startups, investors, and strategic partners. With an AAP, you can join all the live sessions including the Innovator’s Pitch Challenge, investor panels and entrepreneur workshops. This registration option does not include partnering but allows you to take advantage of the educational component of RESI along with the collision factor we see at all our in-person events.
Check out our agenda for Monday, June 5
You can also view the investors who are attending RESI Boston June on our RESI Conference Website which we update frequently so you know who will be a good fit for you to meet in June.
Investor Panel
Innovator’s Pitch Challenge
Entrepreneur Workshop
Want to learn more about RESI and how you can take advantage of the AAP? Reach out to your BD manager and we’d love to answer any questions you may have and learn more about your startup company’s fundraising goals.
|
Life Science Nation Business Development Team
|
|||
|
International
|
East Coast (USA) & China
|
Midwest (USA)
& Canada |
West Coast (USA)
|
 |
 |
|
 |
|
Greg Mannix
Vice President International Business Development Book a Meeting Email Me |
Candice He
VP, Business Development & Global Investment Strategist Book a Meeting Email Me |
Antoinette Lowre
Manager of Business Development Book a Meeting Email Me |
Cameron Hurlburt
Manager of Business Development Book a Meeting Email Me |
Global Tech Hub Gathering in Boston
4 MayBy Erika Wu, Business Development Manager, Global Tech Hubs, LSN
Don’t miss your chance to interact with tech hubs at RESI Boston in June. Tech hubs are a crucial part of the Life Science Nation (LSN) and RESI community as they provide capital, entrepreneurial support, lab space, and economic development for their cohort of aspiring scientist-entrepreneur and fundraising executives. With this immense support from tech hubs, their group of startups, who’ve raised less than $2M USD, can accelerate their entrepreneurship journey by participating in RESI at a discounted rate and taking advantage of LSN services. Ranging from universities, non-profits, incubators, accelerators, and regional and government organizations, they are all looking to connect with investors, strategic partners, and early-stage life science startups in Boston.
Don’t see your organization on this list? Contact us to learn more about the Super Early Bird rate and discounted sponsorship levels for your tech hub and startups.
RESI Boston June 2023 Featured Tech Hubs
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Hot Investor Mandate: Multi-Billion Corporation in Middle East Actively Seeks Investments in Therapeutics, Diagnostics, and Digital Health
4 MayA multibillion corporation headquartered in Saudi Arabia has a venture arm that invests in healthcare. The firm started as an end-to-end logistics and commercialization partner for healthcare products (including pharmaceuticals and medical devices) mainly for global blue chips, with manufacturing facilities in partnership with large corporations. The corporation’s venture arm will be contributing to investments in biotech companies in Series A and later stage companies.
Initial investments will range from $3M-5M in the form of a combination of equity and cash or non-diluted equity if the company has assets that could be leveraged in Saudi Arabia, which includes performing clinical research, manufacturing, and/or commercialization. The firm is predominantly interested in innovative therapeutics, digital health, and personalized diagnostics and with a preference for companies prioritizing US FDA and/or EMA approval. For therapeutics, the firm prefers clinical stage companies. For digital health and diagnostics, the firm prefers companies that have beta tested their product/platforms.
Within therapeutics, the firm is focused on cell and gene therapy in Phase 2 and/or moving into Phase 3, with expectations for accelerated approvals. There are several indications of interest, including rare diseases, oncology, neurodegeneration, immunology, metabolic diseases, therapeutic vaccines, and regenerative therapeutics. Within digital health and diagnostics, the firm is primarily interested in technologies that are enterprise solutions, provider prescribed, personalized medicine or drug discovery engines.
The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the Gulf and Middle Eastern regions. Relocation is not required, however, a carveout or partnership at least in Saudi Arabia and other Gulf countries is necessary. The firm does not require a board seat but does prefer an observer seat after equity investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 